FDA
-
-
-
-
-
-
-
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
-
-
-
-
-
-
-
Cardiol Therapeutics Announces Year-End 2025 Update on Operations
-
-
-
-
-
-
-
Cardiol Therapeutics raises $13.5 million in bought deal financing
-
-
-
-
-
-
-
Cardiol Therapeutics receives U.S. patent allowance for heart drugs through 2040
-
-
-
-
-
-
-
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
-
-
-
-
-
-
-
Cardiol Therapeutics (CRDL) Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
-
-
-
-
-
-
-
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Dr
-
327,799 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

